Citations

Clear

171 citation(s) found for "Moss, M".

Long-term outcomes of liver transplantation (LT) for the treatment of neuroendocrine liver metastases (NELM): The Mayo Clinic experience.
Ahn, Daniel H. , Mathur, Amit K. , DeLeon, Thomas, Hálfdánarson, Þorvarður R. , Hobday, Timothy J. , Ramanathan, Ramesh K., Mody, Kabir , Stucky, Chee‐Chee , Truty, Mark J. , Moss, Adyr A. , Halfdanarson, Thorvardur R , Sonbol, Mohamad Bassam , Buras, Matthew , Borad, Mitesh J. , Gores, Gregory J. , Heimbach, Julie K. , Taner, C. Burcin , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 355-355

10.1200/jco.2018.36.4_suppl.355 Get It

355 Background: In this study, we sought to determine the prognostic factors impacting survival of patients with NELM who underwent LT at Mayo Clinic. Methods: We performed a three-site retrospective analysis of patients with unresectable NELM treated with LT from 1990 -2017. Cases were identified from clinical databases at Mayo Clinic. Data on demographics, timing of diagnosis and transplant, extent of liver involvement, and tumor grade, were extracted. Extent of liver involvement was calculated using previously validated standardized volumetry with high defined as > 25% increase in the weight of the extracted liver at the time of the transplant as compared to the standard liver volume. Survival was calculated using the Kaplan–Meier method. Results: We identified 37 patients. Median age at LT was 47 (range 17.0-64.0), male: female (73% vs. 27%, respectively). Primary tumor site was in the pancreas in 51.3% and in the small bowels in 43.2%; 78.4% had NELM at presentation. While primary tumor resection was done at the time of LT in 5 (13.9%) cases, most patients (80.6%) had ˃6-months interval between primary tumor resection and LT surgery. Prior to LT, 25 (74.3%) patients received somatostatin analogues and 18 (61.3%) had liver-directed therapy. Median time from diagnosis to transplant was 33.6 months (0-246). High extent of liver involvement was identified in 12 patients (33.3%). Disease-Free Survival (DFS) at 3, 5, and 10 years was 56.8%, 43.1%, and 22.4% respectively. Overall-survival (OS) at 3, 5, and 10 years was 86.9%, 79.6%, and 52.6% respectively. High extent of liver involvement at the time of transplantation was associated with inferior DFS and OS and patients˃45 years-old at the time of transplantation had worse DFS. Patients whose disease met the OPTN (Organ Procurement and Transplantation Network) criteria for NELM transplantation had significantly better DFS and OS with median 10-year OS of 80.7 % vs. 17%. Conclusions: LT is a reasonable therapeutic option for selected patients with unresectable NELM with 10-year OS of 52.6%. High extent of liver involvement was associated with worse long-term outcomes while meeting OPTN criteria resulted in best outcomes.
430: REDUCTION OF INAPPROPRIATE PROTON PUMP INHIBITOR USE IN A MIXED INTENSIVE CARE UNIT
Peacock, Sarah , Mourad, Hesham , Moss, John, Moss, John E.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 195-195

10.1097/01.ccm.0000551182.32145.bd Get It

446: RECOGNIZING THE RARITY: A CASE OF A GASTROINTESTINAL HEMORRHAGE FROM AN UNUSUAL SOURCE
Patel, Sheetal , Zaki, Omar M. , Pattanaik, Swetapadma, Umadat, Deviani, Burnside, Rebecca, Trautman, Christopher L. , Werlang, Monia E., Stark, Mark E., Moss, John, Zaki, Omar, Pattanaik, Sweta, Croome, Kristopher P. , Moss, John E. , Guru, Pramod

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 203-203

10.1097/01.ccm.0000551198.06673.54 Get It

Equivalent Outcomes With Retransplantation and Primary Liver Transplantation in the Direct-acting Antiviral Era
Croome, Kristopher P. , Mathur, Amit K. , Pungpapong, Surakit , Lee, David D. , Moss, Adyr A. , Rosen, Charles B. , Taner, C. Burcin , Croome, Kris P , Lee, David D , Pungpapong, Surakit , Heimbach, Julie K.

Mayo Clinic

Transplantation | September 29, 2018 | Volume: 103 | Issue: 6 | Pages: 1168-1174

10.1097/tp.0000000000002460 | PMID 30247315 Get It

Background. The present multicenter study investigated whether equivalent outcomes to primary liver transplant (LT) could be achieved with liver retransplant (reLT) and whether improvements in outcomes have taken place over time, particularly in the direct-acting antiviral era. Methods. All reLT performed at Mayo Clinic Florida, Mayo Clinic Rochester, and Mayo Clinic Arizona were divided into era 1 (2002–2007), era 2 (2008–2012), and era 3 (2013–2017) based on the date of reLT. Results. Improvement in graft survival (GS) after reLT was seen over the 3 eras (P < 0.001). In era 1, GS after reLT was inferior to primary LT (P < 0.001), whereas no difference was seen between reLT and primary LT in era 2 (P = 0.68) or era 3 (P = 0.36). A significantly higher proportion of patients achieved sustained viral response (SVR) within the first year after reLT in each subsequent era (era 1: 10.3%, era 2: 22.5%, and era 3: 100%) (P < 0.001). Graft survival was superior in patients undergoing reLT for recurrent hepatitis C virus who achieved SVR after reLT compared with those who did not (P = 0.03). Conclusions. Results similar to primary LT were achieved in era 3. These improvements coincide with the availability of direct-acting antivirals, which resulted in a 100% SVR rate in era 3 and a decrease in the number of patients undergoing reLT for recurrent hepatitis C virus. The historic dogma that reLT results in inferior outcomes should be revisited.
Assessing clinical outcomes following liver transplantation in intrahepatic cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma patients: The Mayo Clinic experience.
DeLeon, Thomas, Lee, David D. , Girardo, Marlene , Rosen, Charles B. , Moss, Adyr A. , Mathur, Amit K. , Harnois, Denise M. , Aqel, Bashar , Rizvi, Sumera, Mody, Kabir , Lee, David D , Salomao, Marcela , Heimbach, Julie K. , Aqel, Bashar A. , Sonbol, Mohamad Bassam , Kosiorek, Heidi , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16114-e16114

10.1200/jco.2018.36.15_suppl.e16114 Get It

Cardiorespiratory Fitness (Peak Oxygen Uptake): Safe and Effective Measure for Cardiovascular Screening Before Kidney Transplant
Chakkera, Harini A. , Angadi, Siddhartha S. , Heilman, Raymond L. , Scott, Robert L. , Bollempalli, Harini, Cha, Stephen S., Khamash, Hasan , Huskey, Janna L. , Nair, S. , Singer, Andrew L., Reddy, Kunam S. , Mathur, Amit K. , Moss, Adyr A. , Hewitt, Winston R. , Qaqish, Ibrahim , Behmen, Senaida, Keddis, Mira T. , Unzek, Samuel , Steidley, D. Eric , Khamash, Hasan A, Mour, Girish K., Sukumaran Nair, Sumi, Kaplan, Bruce , Cha, Stephen S., Mour, Girish , Chakkera, Harini A

Mayo Clinic

Journal of the American Heart Association | May 31, 2018 | Volume: 7 | Issue: 11 | Pages: No page available

10.1161/jaha.118.008662 | PMID 29853444 Get It

Background Significant heterogeneity exists in practice patterns and algorithms used for cardiac screening before kidney transplant. Cardiorespiratory fitness, as measured by peak oxygen uptake (VO 2peak ), is an established validated predictor of future cardiovascular morbidity and mortality in both healthy and diseased populations. The literature supports its use among asymptomatic patients in abrogating the need for further cardiac testing. Methods and Results We outlined a pre–renal transplant screening algorithm to incorporate VO 2peak testing among a population of asymptomatic high‐risk patients (with diabetes mellitus and/or >50 years of age). Only those with VO 2peak <17 mL/kg per minute (equivalent to <5 metabolic equivalents) underwent further noninvasive cardiac screening tests. We conducted a retrospective study of the a priori dichotomization of the VO 2peak <17 versus ≥17 mL/kg per minute to determine negative and positive predictive value of future cardiac events and all‐cause mortality. We report a high (>90%) negative predictive value, indicating that VO 2peak ≥17 mL/kg per minute is effective to rule out future cardiac events and all‐cause mortality. However, lower VO 2peak had low positive predictive value and should not be used as a reliable metric to predict future cardiac events and/or mortality. In addition, a simple mathematical calculation documented a cost savings of ≈$272 600 in the cardiac screening among our study cohort of 637 patients undergoing evaluation for kidney and/or pancreas transplant. Conclusions We conclude that incorporating an objective measure of cardiorespiratory fitness with VO 2peak is safe and allows for a cost savings in the cardiovascular screening protocol among higher‐risk phenotype (with diabetes mellitus and >50 years of age) being evaluated for kidney transplant.
Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension
Helgeson, Scott A. , Imam, J. Saadi , Moss, John E. , Hodge, David O. , Burger, Charles D. , Helgeson, Scott A , Burger, Charles

Mayo Clinic

Diseases | May 3, 2018 | Volume: 6 | Issue: 2 | Pages: 33

10.3390/diseases6020033 | PMID 29723983 Get It

Pulmonary arterial hypertension (PAH) is a progressive disease that requires validated biomarkers of disease severity. While PAH is defined hemodynamically by right heart catheterization (RHC), brain natriuretic peptide (BNP) is recommended by guidelines to assess disease status. Retrospectively collected data in 138 group 1 PAH patients were examined for the correlation of BNP levels to simultaneously obtained right heart catheterization (RHC). Patients were mostly Caucasian women, with functional class III symptoms, mean BNP of 406 ± 443 pg/mL, and an average right atrial pressure (RAP) of 9.9 ± 5.7 mm Hg and mean pulmonary artery pressure (mPAP) of 47.3 ± 14.7 mm Hg. Significant correlation was demonstrated between BNP and RAP (p = 0.021) and mPAP (p = 0.003). Additional correlation was seen with right heart size on echocardiography: right atrial (RAE; p = 0.04) and right ventricular enlargement (p = 0.03). An increased BNP level was an independent predictor of mortality (p < 0.0001), along with RAP (p = 0.039) and RAE (p = 0.018). Simultaneous collection of BNP at the time of RHC confirmed the correlation of BNP with right heart hemodynamics. The current results reinforce the use of BNP level as a continuous variable to assess disease severity in group 1 PAH.
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States†
Khurmi, Narjeet , Chang, Yu‐Hui, Steidley, D. Eric , Singer, Andrew L., Hewitt, Winston R. , Reddy, Kunam , Moss, Adyr A. , Mathur, Amit K.

Mayo Clinic

Liver Transplantation | March 15, 2018 | Volume: 24 | Issue: 10 | Pages: 1398-1410

10.1002/lt.25055 | PMID 29544033 Get It

Cardiovascular disease (CVD) is a leading cause of post–liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals. Using a merged data set from the 2002‐2011 Nationwide Inpatient Sample and the American Hospital Association Annual Survey, we evaluated liver transplant patients admitted primarily with myocardial infarction (MI), stroke (cerebrovascular accident [CVA]), congestive heart failure (CHF), dysrhythmias, cardiac arrest (CA), or malignant hypertension. Patient‐level data include demographics, Charlson comorbidity index, and CVD diagnoses. Facility‐level variables included ownership status, payer‐mix, hospital resources, teaching status, and physician/nursing‐to‐bed ratios. We used generalized estimating equations to evaluate patient‐ and hospital‐level factors associated with mortality. There were 4763 hospitalizations that occurred in 153 facilities (transplant hospitals, n = 80). CVD hospitalizations increased overall by 115% over the decade (P < 0.01). CVA and MI declined over time (both P < 0.05), but CHF and dysrhythmia grew significantly (both P < 0.03); a total of 19% of hospitalizations were for multiple CVD diagnoses. Transplant hospitals had lower comorbidity patients (P < 0.001) and greater resource intensity including presence of cardiac intensive care unit, interventional radiology, operating rooms, teaching status, and nursing density (all P < 0.01). Transplant and nontransplant hospitals had similar unadjusted mortality (overall, 3.9%, P = 0.55; by diagnosis, all P > 0.07). Transplant hospitals had significantly longer overall length of stay, higher total costs, and more high‐cost hospitalizations (all P < 0.05). After risk adjustment, transplant hospitals were associated with higher mortality and high‐cost hospitalizations. In conclusion, CVD after liver transplant is evolving and responsible for growing rates of inpatient care. Transplant hospitals are associated with poor outcomes, even after risk adjustment for patient and hospital characteristics, which may be attributable to selective referral of certain patient phenotypes but could also be related to differences in quality of care. Further study is warranted.
Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a “Traceback” approach
Moss, Haley , Samimi, Goli , Sherman, Mark E. , Moss, Haley A , Havrilesky, Laura Jean , Myers, Evan R.

Mayo Clinic

Genetic Epidemiology | November 30, 2017 | Volume: 42 | Issue: 1 | Pages: 117-122

10.1002/gepi.22095 | PMID 29193313 Get It

ABSTRACTU.S. guidelines recommend BRCA1/2 mutation testing for women diagnosed with high‐grade ovarian cancer (HGOC) to increase recognition of carriers, but most remain unidentified and at risk. Accordingly, an approach termed “Traceback” has been proposed in which probands are retrospectively identified by testing archived pathology specimens, and family members are traced to provide genetic counseling and testing. We used population‐based data to estimate the number of family members who might be contacted through such a program. We used incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate the number of women diagnosed with HGOC from 2005 to 2016, and census data to estimate the number of spouses, offspring, and siblings (both sexes). Using overall survival for HGOC from SEER and all‐cause mortality rates from the Centers for Diseases Control and Prevention, we estimated the number of patients, spouses, offspring, and siblings of HGOC cases living in 2017. Due to the high mortality rate of HGOC, consent from living probands may be possible in only 42% of the cases; consent to test pathology specimens would need to be sought from next of kin for the remainder. In 2017, an estimated 406,919 living next of kin (spouses, siblings, offspring) would be available for potential consent. Testing archived ovarian cancer pathology specimens may enable the identification of BRCA1/2 mutation carriers, but consent from next of kin would be required in in 58% of cases. Although Traceback offers the possibility of identifying unaffected BRCA1/2 mutation carriers, pilot feasibility studies that include assessment of methods to secure consent are needed.
Central Line Proficiency Test Outcomes after Simulation Training versus Traditional Training to Competence
Alsaad, Ali A., Bhide, Vandana Y., Moss, Jimmy L., Silvers, Scott M., Johnson, Margaret M. , Maniaci, Michael J.

Mayo Clinic

Annals of the American Thoracic Society | March 6, 2017 | Volume: 14 | Issue: 4 | Pages: 550-554

10.1513/annalsats.201612-987oc | PMID 28145736 Get It

Abstract Rationale Studies have shown the importance of simulation-based training on the outcomes of central venous catheter (CVC) insertion by trainees. Objectives To compare the performance of internal medicine trainees who underwent standardized simulation training of CVC insertion with that of internal medicine trainees who had traditional CVC training and were already deemed competent to perform the procedure during a proficiency evaluation using a training mannequin. Methods Trainees who perform CVC insertion were enrolled in the institutional Central Line Workshop, which includes both an online and an experiential simulation component. The training is followed by a certification station proficiency assessment. Residents and fellows previously certified competent to perform CVC placement without supervision completed the online module, but they could opt out of the experiential component and proceed directly to the evaluation. Results Forty-eight trainees participated in the study. Twenty-one (44%), 15 (31%), 6 (13%), 1 (2%), 2 (4%), and 3 (6%) were in postgraduate year 1 (PGY1), PGY2, PGY3, PGY4, PGY5, and PGY6, respectively. Twenty-nine completed the hands-on instruction, 28 (97%) of whom successfully passed the simulation-based assessment on their first attempt. Nineteen trainees previously credentialed to perform CVC placement without supervision opted out of the simulation-based experiential training. Of these, five (26%) failed in their first attempt (P = 0.02 vs. trainees who completed the simulation training). Conclusions Standardized simulation-based training can improve CVC insertion proficiency, even among trainees with previous experience sufficient to have been deemed competent in the procedure. Improved performance at simulation-based testing may translate to improved outcomes of CVC placement by trainees.